Sam Thiagalingam PhD

Associate Professor, Biomedical Genetics

Associate Professor, Pathology & Laboratory Medicine

72 East Concord Street | (617) 358-3688
Sam Thiagalingam
Sections

Biomedical Genetics

Centers

BU-BMC Cancer Center

Evans Center for Interdisciplinary Biomedical Research

Biography

Dr. Thiagalingam is an expert cancer geneticist and was the first to show that SMAD4 inactivation is a critical event during the late stages of colon cancer progression. He was a lead researcher in the team that first identified a family of five novel SMAD genes. He also proposed a simple minded multi-modular molecular network (MMMN) cancer progression model as a road map to visualize the various gene alterations in modules of networks of pathways. Recently, his studies found that intact hyperactive TGFß-Smad signaling is required to sustain “epigenetic memory” responsible for epithelial-mesenchymal transition (EMT), a critical step during conversion to malignant cancer. His long-term goal is to identify novel cancer biomarkers and therapeutic targets by contributing to the “big picture” of interconnected network of events that mediate cancer progression to metastasis using breast and colon cancers as the model systems.

Other Positions

Education

PhD, Johns Hopkins University, 1992

MS, Bowling Green State University, 1986

BSc, University of Jaffna, 1982

Publications

Published on 7/28/2021

Abdolmaleky HM, Zhou JR, Thiagalingam S. Cataloging recent advances in epigenetic alterations in major mental disorders and autism. Epigenomics. 2021 Aug; 13(15):1231-1245. PMID: 34318684.

Published on 1/23/2020

Thiagalingam S. Epigenetic memory in development and disease: Unraveling the mechanism. Biochim Biophys Acta Rev Cancer. 2020 04; 1873(2):188349. PMID: 31982403.

Published on 1/13/2020

Wong CK, Lambert AW, Ozturk S, Papageorgis P, Lopez D, Shen N, Sen Z, Abdolmaleky HM, Gyorffy B, Feng H, Thiagalingam S. Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan. Mol Cancer Res. 2020 03; 18(3):414-423. PMID: 31932471.

Published on 3/28/2019

Wong CK, Gromisch C, Ozturk S, Papageorgis P, Abdolmaleky HM, Reinhard BM, Thiagalingam A, Thiagalingam S. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer. Cancer Biol Ther. 2019; 20(8):1113-1120. PMID: 30922194.

Published on 2/5/2019

Kalli M, Mpekris F, Wong CK, Panagi M, Ozturk S, Thiagalingam S, Stylianopoulos T, Papageorgis P. Activin A Signaling Regulates IL13Ra2 Expression to Promote Breast Cancer Metastasis. Front Oncol. 2019; 9:32. PMID: 30805303.

Published on 11/23/2018

Abdolmaleky HM, Gower AC, Wong CK, Cox JW, Zhang X, Thiagalingam A, Shafa R, Sivaraman V, Zhou JR, Thiagalingam S. Aberrant transcriptomes and DNA methylomes define pathways that drive pathogenesis and loss of brain laterality/asymmetry in schizophrenia and bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2019 03; 180(2):138-149. PMID: 30468562.

Published on 10/18/2016

Nohesara S, Ghadirivasfi M, Barati M, Ghasemzadeh MR, Narimani S, Mousavi-Behbahani Z, Joghataei M, Soleimani M, Taban M, Mehrabi S, Thiagalingam S, Abdolmaleky HM. Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes. Am J Med Genet B Neuropsychiatr Genet. 2016 Dec; 171(8):1180-1189. PMID: 27753212.

Published on 1/6/2016

Ozturk S, Papageorgis P, Wong CK, Lambert AW, Abdolmaleky HM, Thiagalingam A, Cohen HT, Thiagalingam S. SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis. Proc Natl Acad Sci U S A. 2016 Jan 19; 113(3):638-43. PMID: 26739564.

Published on 10/27/2015

Lambert AW, Wong CK, Ozturk S, Papageorgis P, Raghunathan R, Alekseyev Y, Gower AC, Reinhard BM, Abdolmaleky HM, Thiagalingam S. Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells. Mol Cancer Res. 2016 Jan; 14(1):103-13. PMID: 26507575.

Published on 8/18/2015

Abdolmaleky HM, Pajouhanfar S, Faghankhani M, Joghataei MT, Mostafavi A, Thiagalingam S. Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and Psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2015 Dec; 168(8):687-96. PMID: 26285059.

View full list of 53 publications.